BioShai

Company Overview

Snapshot

Founded in January 2014, BioShai is a non-active company with 1–10 employees. The company has secured funding across two rounds from Youdim Pharmaceuticals. Co-founder Martin Rabey helped establish the company, which ceased operations in October 2022.

Business overview

BioShai is a Health Tech & Life Sciences company focused on developing diagnostic solutions. Its core product, PDx, is a blood test designed for the early detection of Parkinson's disease. This test utilizes the measurement of gene expression levels, which can be integrated with other clinical data to provide a comprehensive diagnosis and guide treatment decisions for physicians. The company operates within the biotechnology, diagnostics, and genomics sectors, serving hospitals, clinics, and healthcare providers.

Strategic signal

In November 2016, BioShai's PDx blood test for Parkinson's disease was highlighted as the world's first, signaling a significant advancement in early diagnosis for the neurodegenerative condition. This development indicated the potential for a less invasive and more accessible diagnostic tool, which could profoundly impact patient care and disease management within the medical community.

Company Intelligence Q&A

What is BioShai's primary product?

BioShai's primary product is PDx, a blood test designed for the early diagnosis of Parkinson's disease, based on measuring gene expression levels.

When was BioShai founded?

BioShai was founded in January 2014.

What is the operational status of BioShai?

BioShai is currently non-active and ceased operations in October 2022.